vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Ladder Capital Corp (LADR). Click either name above to swap in a different company.
Ladder Capital Corp is the larger business by last-quarter revenue ($22.3M vs $15.0M, roughly 1.5× CHAMPIONS ONCOLOGY, INC.). Ladder Capital Corp runs the higher net margin — 71.0% vs 1.8%, a 69.3% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -18.0%). Ladder Capital Corp produced more free cash flow last quarter ($78.7M vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -22.5%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Ladder Capital Corp is a leading commercial real estate finance firm operating primarily across the United States. It originates and manages a diversified portfolio of senior secured commercial mortgage loans, mezzanine debt, commercial mortgage-backed securities, and direct real estate assets, serving property owners, operators and developers across major market segments.
CSBR vs LADR — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $22.3M |
| Net Profit | $268.0K | $15.9M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 69.5% |
| Net Margin | 1.8% | 71.0% |
| Revenue YoY | 11.5% | -18.0% |
| Net Profit YoY | -63.2% | -49.4% |
| EPS (diluted) | $0.02 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $22.3M | ||
| Q3 25 | $14.0M | $27.8M | ||
| Q2 25 | $12.4M | $21.5M | ||
| Q1 25 | $17.0M | $20.3M | ||
| Q4 24 | $13.5M | $27.2M | ||
| Q3 24 | $14.1M | $38.4M | ||
| Q2 24 | $14.0M | $34.3M | ||
| Q1 24 | $12.0M | $37.1M |
| Q4 25 | $268.0K | $15.9M | ||
| Q3 25 | $-436.0K | $19.2M | ||
| Q2 25 | $-1.8M | $17.1M | ||
| Q1 25 | $4.5M | $11.6M | ||
| Q4 24 | $728.0K | $31.3M | ||
| Q3 24 | $1.3M | $27.6M | ||
| Q2 24 | $-109.0K | $32.1M | ||
| Q1 24 | $-2.5M | $16.4M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 69.5% | ||
| Q3 25 | -3.8% | 72.4% | ||
| Q2 25 | -16.2% | 96.7% | ||
| Q1 25 | 26.4% | 52.7% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.5% | 74.1% | ||
| Q2 24 | -1.9% | 90.4% | ||
| Q1 24 | -21.4% | 49.4% |
| Q4 25 | 1.8% | 71.0% | ||
| Q3 25 | -3.1% | 69.0% | ||
| Q2 25 | -14.9% | 79.5% | ||
| Q1 25 | 26.4% | 56.8% | ||
| Q4 24 | 5.4% | 115.1% | ||
| Q3 24 | 9.3% | 71.7% | ||
| Q2 24 | -0.8% | 93.6% | ||
| Q1 24 | -21.1% | 44.2% |
| Q4 25 | $0.02 | $0.13 | ||
| Q3 25 | $-0.03 | $0.15 | ||
| Q2 25 | $-0.12 | $0.14 | ||
| Q1 25 | $0.31 | $0.09 | ||
| Q4 24 | $0.05 | $0.25 | ||
| Q3 24 | $0.09 | $0.22 | ||
| Q2 24 | $-0.01 | $0.26 | ||
| Q1 24 | $-0.19 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $38.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $1.5B |
| Total Assets | $30.2M | $5.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $38.0M | ||
| Q3 25 | $10.3M | $49.4M | ||
| Q2 25 | $9.8M | $134.9M | ||
| Q1 25 | $3.2M | $479.8M | ||
| Q4 24 | $2.8M | $1.3B | ||
| Q3 24 | $2.9M | $1.6B | ||
| Q2 24 | $2.6M | $1.2B | ||
| Q1 24 | $4.5M | $1.2B |
| Q4 25 | $4.2M | $1.5B | ||
| Q3 25 | $3.5M | $1.5B | ||
| Q2 25 | $3.8M | $1.5B | ||
| Q1 25 | $5.5M | $1.5B | ||
| Q4 24 | $681.0K | $1.5B | ||
| Q3 24 | $-332.0K | $1.5B | ||
| Q2 24 | $-1.9M | $1.5B | ||
| Q1 24 | $-2.1M | $1.5B |
| Q4 25 | $30.2M | $5.2B | ||
| Q3 25 | $30.5M | $4.7B | ||
| Q2 25 | $32.3M | $4.5B | ||
| Q1 25 | $30.6M | $4.5B | ||
| Q4 24 | $25.2M | $4.8B | ||
| Q3 24 | $24.9M | $4.8B | ||
| Q2 24 | $26.1M | $4.8B | ||
| Q1 24 | $26.8M | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $87.0M |
| Free Cash FlowOCF − Capex | $-2.0M | $78.7M |
| FCF MarginFCF / Revenue | -13.1% | 352.4% |
| Capex IntensityCapex / Revenue | 1.6% | 37.4% |
| Cash ConversionOCF / Net Profit | -6.47× | 5.49× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $118.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $87.0M | ||
| Q3 25 | $600.0K | $26.3M | ||
| Q2 25 | $6.9M | $44.0M | ||
| Q1 25 | $490.0K | $-28.7M | ||
| Q4 24 | $-283.0K | $133.9M | ||
| Q3 24 | $311.0K | $169.0M | ||
| Q2 24 | $-1.8M | $45.4M | ||
| Q1 24 | $-919.0K | $-20.4M |
| Q4 25 | $-2.0M | $78.7M | ||
| Q3 25 | $554.0K | $25.9M | ||
| Q2 25 | $6.6M | $43.4M | ||
| Q1 25 | $448.0K | $-29.6M | ||
| Q4 24 | $-377.0K | $127.4M | ||
| Q3 24 | — | $166.0M | ||
| Q2 24 | $-1.8M | $44.9M | ||
| Q1 24 | $-1.0M | $-21.7M |
| Q4 25 | -13.1% | 352.4% | ||
| Q3 25 | 4.0% | 93.1% | ||
| Q2 25 | 53.5% | 201.6% | ||
| Q1 25 | 2.6% | -145.6% | ||
| Q4 24 | -2.8% | 468.2% | ||
| Q3 24 | — | 432.1% | ||
| Q2 24 | -13.0% | 131.0% | ||
| Q1 24 | -8.4% | -58.6% |
| Q4 25 | 1.6% | 37.4% | ||
| Q3 25 | 0.3% | 1.7% | ||
| Q2 25 | 2.0% | 2.9% | ||
| Q1 25 | 0.2% | 4.3% | ||
| Q4 24 | 0.7% | 23.9% | ||
| Q3 24 | 0.0% | 7.8% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.8% | 3.7% |
| Q4 25 | -6.47× | 5.49× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 2.57× | ||
| Q1 25 | 0.11× | -2.49× | ||
| Q4 24 | -0.39× | 4.27× | ||
| Q3 24 | 0.24× | 6.13× | ||
| Q2 24 | — | 1.41× | ||
| Q1 24 | — | -1.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
LADR
Segment breakdown not available.
